BS_SHMC4902
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- age_years
- 1.745
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.470
- IL6_JAK_STAT3_SIGNALING+0.404
- CHOLESTEROL_HOMEOSTASIS+0.386
- ADIPOGENESIS+0.378
- TGF_BETA_SIGNALING+0.375
- INTERFERON_ALPHA_RESPONSE+0.358
- OXIDATIVE_PHOSPHORYLATION+0.358
- INTERFERON_GAMMA_RESPONSE+0.343
- COMPLEMENT+0.287
- HEDGEHOG_SIGNALING+0.282
Top 10 suppressed
- E2F_TARGETS-0.428
- G2M_CHECKPOINT-0.419
- PANCREAS_BETA_CELLS-0.257
- SPERMATOGENESIS-0.198
- MYC_TARGETS_V1-0.120
- KRAS_SIGNALING_DN-0.103
- MYC_TARGETS_V2-0.098
- MITOTIC_SPINDLE-0.084
- ESTROGEN_RESPONSE_LATE-0.052
- APICAL_SURFACE-0.024
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_BKQZ550R | pilocytic astrocytoma | — | 0.939 |
| 2 | BS_49852ZBH | pilocytic astrocytoma | — | 0.910 |
| 3 | BS_T4JFN54G | low-grade glioma | — | 0.908 |
| 4 | BS_T1W4JA94 | pilocytic astrocytoma | — | 0.896 |
| 5 | BS_0J9SHHSC | low-grade glioma | — | 0.893 |
| 6 | BS_S50KQEXV | low-grade glioma | — | 0.892 |
| 7 | BS_FJWZ3M7V | low-grade glioma | — | 0.892 |
| 8 | BS_S1KK7XRH | low-grade glioma | — | 0.883 |
| 9 | BS_ZZMYDZJW | pilocytic astrocytoma | — | 0.882 |
| 10 | BS_MBSTWZA6 | pilocytic astrocytoma | — | 0.882 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.470 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.404 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.386 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.378 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.375 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.358 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.358 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.343 | Idelalisib | — uncovered |
| COMPLEMENT | 0.287 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.282 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.277 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.253 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.249 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.232 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.228 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.216 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.209 | Idelalisib | — uncovered |
| MYOGENESIS | 0.205 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.193 | Inavolisib | — uncovered |